<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646203</url>
  </required_header>
  <id_info>
    <org_study_id>14549</org_study_id>
    <secondary_id>I5I-IE-JTCA</secondary_id>
    <nct_id>NCT01646203</nct_id>
  </id_info>
  <brief_title>A Study of IMC-TR1 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and tolerability of IMC-TR1 in patients with advanced solid
      tumors, as well as gather evidence of anti-tumor activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first-in-human Phase 1 study of IMC-TR1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase 2 dose of IMC-TR1</measure>
    <time_frame>Baseline to study completion (Approximately 18 Months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of IMC-TR1</measure>
    <time_frame>Baseline through Cycle 1 (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Development of antibodies against IMC-TR1</measure>
    <time_frame>Cycle 1 - Day 1 and Day 29, Cycle 2 - Day 15, Cycle 3 and each consecutive cycle - Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of IMC-TR1 as monotherapy, assessed via tumor measurement by Response Evaluation Criteria in Solid Tumors, Version 1.1</measure>
    <time_frame>Day 36 of every cycle and at 30 day follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the concentration-time curve (AUC) of IMC-TR1</measure>
    <time_frame>0, 1, 2, 4, 8, 24, 48, 96,168, and 336 hours after the first and fifth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum concentration (Cmax) of IMC-TR1</measure>
    <time_frame>0, 1, 2, 4, 8, 24, 48, 96,168, and 336 hours after the first and fifth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Minimum concentration (Cmin) of IMC-TR1</measure>
    <time_frame>0, 1, 2, 4, 8, 24, 48, 96,168, and 336 hours after the first and fifth infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Neoplasms</condition>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>IMC-TR1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A - Dose Escalation:
Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle
Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles
Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles
Part B - Disease Specific Cohort Expansion:
Patients will be enrolled into each of three tumor-specific cohort expansions. Patients will be treated with recommended Phase 2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-TR1</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>IMC-TR1</arm_group_label>
    <other_name>LY3022859</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A and Part B: Patients must be appropriate candidates for experimental therapy,
             with a solid tumor that has failed standard therapy or for which no standard therapy
             is available, and evidence of progressive disease

               -  Part A only: Patients must have histological or cytological evidence of a solid
                  tumor which is advanced and/or metastatic

               -  Part B only: Patient who have failed first-line therapy/standard of care and have
                  histological or cytological evidence of a cancer type for which evidence of
                  activity was observed during Part A or for which preclinical evidence of
                  potential activity has been observed

          -  Have the presence of measurable or nonmeasurable disease as defined by the Response
             Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)

               -  Part A only: Patients may have measurable or nonmeasurable disease

               -  Part B: Patients must have measurable disease

          -  Have adequate organ function including: Hematologic, Hepatic, Albumin, Coagulation and
             Renal function

          -  Have a performance status of ≤ 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale

          -  Have discontinued previous treatments for cancer and recovered from the acute effects
             of therapy

          -  Males and females with reproductive potential must agree to use medically approved
             contraceptive precautions during the study and for 3 months following the last dose of
             study drug

          -  Females with child bearing potential must have had a negative serum pregnancy test and
             must not be breastfeeding

          -  Have an estimated life expectancy that is &gt; 3 months

        Exclusion Criteria:

          -  Have clinically significant cardiac disease, including:

               -  Myocardial infarction within 6 months prior to study entry, unstable angina
                  pectoris, congestive heart failure, or uncontrolled hypertension

               -  Major electrocardiogram (ECG) abnormalities

               -  Major abnormalities documented by echocardiography with Doppler

               -  Have known predisposing conditions that are consistent with development of
                  aneurysms of the ascending aorta or aortic stress

               -  Have QTc interval of &gt; 500 msec on screening ECG

          -  Have other known serious pre-existing medical conditions

          -  Have received prior investigational therapy targeting TGFβ or its receptors

          -  Have a known sensitivity to monoclonal antibodies or other therapeutic proteins, to
             agents of similar biologic composition as IMC-TR1

          -  Have a high risk of gastrointestinal bleeding, active inflammatory bowel disease, or
             chronic steroid use

          -  Are currently using or has received a systemic thrombolytic agent within 28 days prior
             to enrollment

          -  Are receiving:

             â€¢ full-dose warfarin â€¢ intravenous heparin or low-molecular-weight heparin â€¢
             chronic daily treatment with aspirin at a dose greater than 325 mg per day or
             nonsteroidal anti-inflammatory medications known to inhibit platelet function

          -  Have evidence of retinal disease or are a monocular patient

          -  Have received a solid organ transplant, bone marrow transplant or stem cell transplant

          -  Have symptomatic central nervous system (CNS) malignancy or untreated metastasis

          -  Have acute or chronic leukemia

          -  Have a known active fungal, bacterial, and/or viral infection including human
             immunodeficiency virus or viral hepatitis requiring treatment

          -  Has a positive fecal occult blood test within 14 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <pending_results>
    <submitted>September 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

